- Previous Close
19.88 - Open
20.09 - Bid 19.98 x 100
- Ask 20.01 x 100
- Day's Range
19.93 - 20.22 - 52 Week Range
11.89 - 21.67 - Volume
547,968 - Avg. Volume
992,006 - Market Cap (intraday)
2.374B - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
35.71 - EPS (TTM)
0.56 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.14
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
www.catalystpharma.comRecent News: CPRX
View More
Performance Overview: CPRX
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CPRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CPRX
View MoreValuation Measures
Market Cap
2.37B
Enterprise Value
2.00B
Trailing P/E
35.71
Forward P/E
9.82
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.47
Price/Book (mrq)
3.90
Enterprise Value/Revenue
4.61
Enterprise Value/EBITDA
16.34
Financial Highlights
Profitability and Income Statement
Profit Margin
15.69%
Return on Assets (ttm)
9.33%
Return on Equity (ttm)
13.85%
Revenue (ttm)
434.48M
Net Income Avi to Common (ttm)
68.15M
Diluted EPS (ttm)
0.56
Balance Sheet and Cash Flow
Total Cash (mrq)
375.69M
Total Debt/Equity (mrq)
0.55%
Levered Free Cash Flow (ttm)
-3.69M
Research Analysis: CPRX
View MoreCompany Insights: CPRX
CPRX does not have Company Insights
Research Reports: CPRX
View MoreLowering target price to $21.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRaising target price to $21.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $20.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $21.00
CATALYST PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target